Ferriprox Deferiprone

SAME PROVEN EFFICACY

 

FERRIPROX HAS BEEN PROVEN TO REDUCE IRON LEVELS IN
THE HEART AND LIVER AND TO DECREASE SERUM FERRITIN1

 

DECREASE IN CARDIAC IRON LOAD

An approximate 28% mean increase in magnetic resonance imaging (MRI) T2 representing a decrease in cardiac iron load, after 1 year of therapy.1,2

Higher T2 score = lower cardiac iron burden

 
Ferriprox successfully reduced cardiac iron load over 1 year

The clinical significance of this observation is not known.

 

REDUCTION IN LIVER IRON CONCENTRATION (LIC)

At least a 20% reduction in LIC for 42% of patients within 1 year of therapy.2

 
Ferriprox successfully reduced LIC over 1 year (pooled analysis)

The clinical significance of this observation is not known.

 

REDUCTION IN SERUM FERRITIN

962 μg/L mean serum ferritin reduction in all patients in the study within 1 year of therapy.3

At least a 20% reduction in serum ferritin for 50% of patients within 1 year of therapy.1

 
Mean serum ferritin values over 1 year in all patients in the study with iron overload
 

References:

  • 1. Ferriprox (deferiprone) Prescribing Information. ApoPharma USA, 2019.
  • 2. ApoPharma. Oncology Drug Advisory Committee Briefing Document NDA #21-825. Ferriprox (deferiprone) is an iron chelator for the treatment of patients with transfusional iron overload when current chelation therapy is inadequate. 2011.
  • 3. ApoPharma. Core Study Report for Study LA36-0310: Analysis of Data from Clinical Studies of Ferriprox to Evaluate its Efficacy in Patients with Iron Overload for Whom Previous Chelation Therapy Has Been Inadequate. 2011.